Why the study?
Does haloperidol treatment improve symptoms and alter CSF HVA levels in patients with Tourette syndrome?
Does haloperidol treatment improve symptoms and alter CSF HVA levels in patients with Tourette syndrome?
Haloperidol treatment in Tourette syndrome decreases symptoms and increases CSF HVA levels, supporting the hypothesis of dopaminergic receptor supersensitivity.
May support haloperidol for Tourette symptoms with rising CSF HVA; leaves open dopaminergic supersensitivity hypothesis pending controlled trials.
A prospective clinical and biochemical study on the effects of treatment with haloperidol has been performed in seven patients with Tourette syndrome. Pretreatment cerebrospinal fluid levels of homovanillic acid (CSF HVA) were significantly reduce in all patients, whereas 5-hydroxyindoleacetic acid was reduced in only two. With haloperidol treatment, symptoms decreased in all cases (21 to 88%) and clinical improvement was associated with an increased level of CSF HVA, often returning to the normal range. Optimal therapeutic response was found with serum levels of haloperidol between 1 and 4 ng/ml; however, disturbing side effects also occurred within this range. These results support the hypothesis that Tourette syndrome may result from a supersensitivity of dopaminergic receptors.
No takes yet. Share an insight, caveat, or question.
Singer et al. (1982) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: